DDInter519 DDInter1658
Dexlansoprazole is a new-generation proton pump inhibitor (PPI) used for the management of symptoms associated with gastroesophageal reflux disease (GERD) and erosive esophagitis. Dexlansoprazole is the R-enantiomer of, which is composed of a racemic mixture of the R- and S-enantiomers. Compared to the older generation of PPIs (which includes,, and ), dexlansoprazole has a unique pharmacokinetic profile due to its delayed-release and dual-delivery release system: This aims to address some limitations of the older-generation PPIs, such as short plasma half-life and the need for meal-associated dosing.[A19566, A19568, A178084, A174244] Dexlansoprazole inhibits the final step in gastric acid production by blocking the (H+, K+)-ATPase enzyme.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Dexlansoprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Prasugrel
Dexlansoprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Acetylsalicylic acid
Dexlansoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cisplatin
Dexlansoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Plazomicin
Dexlansoprazole {u} may lead to a major life threatening interaction when taken with {v} Methotrexate
Dexlansoprazole {u} may lead to a major life threatening interaction when taken with {v} Neratinib
Dexlansoprazole may cause a minor interaction that can limit clinical effects when taken with Prasugrel
Dexlansoprazole may cause a minor interaction that can limit clinical effects when taken with Acetylsalicylic acid
Dexlansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin
Dexlansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Plazomicin
Dexlansoprazole may lead to a major life threatening interaction when taken with Methotrexate
Dexlansoprazole may lead to a major life threatening interaction when taken with Neratinib